Long-term survivorship care after CAR-T cell therapy.

Autor: Puckrin R; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Jamani K; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Jimenez-Zepeda VH; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2024 Jan; Vol. 112 (1), pp. 41-50. Date of Electronic Publication: 2023 Sep 28.
DOI: 10.1111/ejh.14100
Abstrakt: While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are well-recognized acute toxicities of chimeric antigen receptor (CAR) T cell therapy, these complications have become increasingly manageable by protocolized treatment algorithms incorporating the early administration of tocilizumab and corticosteroids. As CAR-T cell therapy expands to new disease indications and the number of long-term survivors steadily increases, there is growing recognition of the need to appropriately evaluate and manage the late effects of CAR-T cell therapy, including late-onset or persistent neurotoxicity, prolonged cytopenias, delayed immune reconstitution and infections, subsequent malignancies, organ dysfunction, psychological distress, and fertility implications. In this review, we provide a practical approach to the long-term survivorship care of the CAR-T cell recipient, with a focus on the optimal strategies to address the common and challenging late complications affecting this unique population.
(© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: